• Sheraton New York Times Square Hotel (map)
  • 811 7th Avenue
  • New York, NY, 10019
  • United States

Session Chairs: Elizabeth M. Jaffee, Johns Hopkins Medicine, Baltimore, MD and Mark J. Smyth, QIMR Berghofer Institute, Melbourne, Australia

8:00 a.m.  Elizabeth M. Jaffee, Johns Hopkins University School of Medicine, Baltimore, MD
Combinatorial immunotherapies with the potential to reverse the carcinogenesis process

8:30 a.m.  Mark J. Smyth, QIMR Berghofer Medical Research Institute, Queensland, Australia
Novel natural killer cell targets for cancer immunotherapy

9:00 a.m.  Chie Kudo-Saito, National Cancer Center, Tokyo, Japan
Targeting FSTL1 augments therapeutic activities of immune checkpoint inhibitors*

9:15 a.m.  Mark P. Chao, Forty Seven, Inc. Palo Alto, CA
The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies*  

9:30 a.m.  Weiping Zou, University of Michigan School of Medicine, Ann Arbor, MI
Cancer epigenetic and metabolic mechanisms controlling immunotherapy and chemotherapy

10:00 a.m.  Santiago Zelenay, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
Manipulating inflammation to raise cancer immunogenicity

10:30 a.m.  Refreshment Break

* Proffered presentation